Our third Health Technology Assessment and Evidence Synthesis Bulletin of 2024 is out now. It provides a brief summary of our key activities and achievements for the third quarter of the year, including our latest reports, work we’ve recently undertaken, and conferences at which we’ve presented. Key developments include:

• HIQA and partners awarded €2.5 million for continued support of national clinical guidelines
• HTA of adding shingles vaccine to the national immunisation programme for adults
• HTA of extending BowelScreen to those aged 50 to 54 years underway
• Rapid HTA of immunisation against respiratory syncytial virus (RSV)
• HTA of an alternative national emergency phone line for acute, non-urgent medical needs begun
• Presentations at the Global Evidence Summit from 10-13 September in Prague.

Subscribe to receive future issues directly to your inbox at htanews@hiqa.ie.